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Risk disclosure is an essential element of the marketing of prescription drugs and other medical products. This
study examines how consumers respond to verbal information about the frequency and severity of medical-product
risks and how media-induced affect can moderate such responses. The study finds that consumers tend to
overestimate the actual likelihood of adverse events described with words such as “common” or “rare” (compared
with the probabilities such terms are typically intended to convey) and that consumers tend to give little weight to
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severity information and using such information to make inferences about other product attributes (e.g., product
efficacy). These findings suggest that medical marketers and regulators need to devise more effective means of
communicating risk probability to consumers and that positive mood induction (e.g., by placing advertisements in
upbeat media environments) can enhance consumers’ ability to process product risk information.
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For many years, consumers have been exposed toproduct risk statements, ranging from health warn-ings in tobacco advertising to financial loss dis-
claimers in mutual fund advertisements (Hoy and Andrews
2004). However, the prevalence and prominence of such
warnings have increased dramatically in recent years, with
the rapid growth of direct-to-consumer (DTC) marketing of
prescription drugs and medical devices. When the Food and
Drug Administration (FDA) was created in the early twenti-
eth century, consumer drug advertising was still associated
with the misleading claims of nineteenth-century “snake
oil” purveyors. Therefore, the FDA required manufacturers
of prescription drugs to limit their promotional efforts to
physicians, pharmacists, and other health care profession-
als. However, beginning in the late 1980s, the FDA began to
relax the rules on consumer advertising of prescription
drugs, setting off an accelerating growth in DTC advertising
over the next two decades, from $12 million in 1989
(Calfee 2002) to $4.8 billion in 2007 (Pharma Marketletter
2009).
However, DTC advertising has important regulatory
restraints. The FDA (1999) mandates that any DTC adver-
tisement that mentions both a brand name (e.g., Lipitor) and
its purpose (e.g., reducing serum cholesterol) must also
contain a “major statement” of product risks within the
advertisement’s main body. The risks described in DTC
advertisements vary from severe (e.g., liver damage, birth
defects) to fairly mild side effects (e.g., dry mouth, drowsi-
ness) and also vary in reported likelihood. Thus, some
adverse events are described as “rare” or “very rare,” and
others are described as “common” or “commonly reported.”
Indeed, FDA (2004) guidelines suggest that both the most
serious risks and the three to five most frequently occurring
risks should be mentioned.
The implicit assumption of such risk disclosure is that
consumers will be able to appropriately interpret and weigh
risk information to make informed health care choices (e.g.,
Calfee 2002; FDA 2004). Many models of health care deci-
sion making (e.g., protection motivation theory, health
belief model; see Berry 2004; Schwarzer 2001) can be clas-
sified as “expectancy models,” which imply that consumers
are rational in their decision making and use a version of a
weighted sum model to process and use available informa-
tion. This suggests that consumers assign a probability esti-
mate to the likelihood descriptors (e.g., “rare” = 1% of the
time) and severity descriptors (e.g., a “severe” headache
feels twice as bad as a “mild” headache) and then form
global product evaluations by weighting the disutility of
potential outcomes by their subjective probabilities.
The empirical research that exists on how consumers
actually interpret risk disclosures in DTC advertisements is
sparse and somewhat contradictory. Some studies suggest
that product risk disclosures can significantly lower con-
sumers’ product evaluations (e.g., Goetzl 2001), recall of
product benefits (Morris, Mazis, and Brinberg 1989), and
product use compliance (Wosinska 2005). Other studies
suggest that consumers often ignore risk disclosures (e.g.,
Menon et al. 2003), and some have even suggested that
such risk statements can actually enhance consumers’ prod-
uct evaluations (e.g., Goetzl 2000). More recent research
has suggested that consumers subjectively evaluate product
risk statements depending on whether statements of product
benefits are gain or loss framed (Cox, Cox, and Zimet
2006). However, little is known about the contingencies that
govern whether advertised risk disclosures have a negative,
neutral, or positive impact on consumer brand attitudes and
intentions. The need for research in this area is stressed in
an FDA (2004, p. 7) report, which concludes “we have not
evaluated how presenting the information in different for-
mats affects consumer comprehension, and we believe that
there is much more to be learned before we develop final
guidance on how best to inform patients about the drugs
being promoted.”
To that end, the current research examines how con-
sumers respond to advertised disclosures of drug risks that
vary in severity and frequency. Specifically, we address the
following questions:
1. How do consumers interpret the “probability language”
typically used to describe the likelihood of potential adverse
product events (i.e., terms such as “very common” and
“very rare”)? Do these terms mean the same thing to con-
sumers as they do to advertisers and regulators?
2. What evaluative weight do consumers give to the stated
severity of a potential adverse product event versus its stated
likelihood (frequency) of occurring? Many models of risky
decision making suggest that consumers will (or should)
give considerable weight to both severity and likelihood and
that these two factors should be combined in forming global
product evaluations. Do these models accurately describe
consumer evaluations of advertised risk disclosures?
3. Do consumers’ responses to product risk disclosures vary
depending on the media context in which the product risk
message appears? Specifically, how does media-induced
mood influence the ways consumers respond to product risk
information?
In the following section, we discuss previous research and
theory relevant to these questions. Then, we report the
results of an experiment that examines these issues empiri-
cally. Finally, we discuss the implications of the findings
and directions for further research.
Theory and Hypotheses
Consumer Interpretation of Probability Words
Many models of risky decision making (e.g., expectancy–
value models; Eagly and Chaiken 1993) posit that con-
sumers weigh information about the likelihood of adverse
events in evaluating risky products. However, research indi-
cates that people often have difficulty understanding
numerical risk expressions, such as probabilities and per-
centages (Berry 2004; Kahneman and Tversky 1979;
Loewenstein et al. 2001). Thus, most consumer information
on product risks (including risk disclosures in DTC drug
advertisements) describes the likelihood of adverse events
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with familiar probability words, such as “rare,” “common,”
and “uncommon.”
In the European Union (EU), the European Commission
has tried to increase the precision and consistency with
which such words are used in product labeling and promo-
tion by providing specific guidelines for translating numeri-
cal risk probabilities into probability words (e.g., “very
common” side effects occur in >10% of patients, “com-
mon” side effects occur in 1%–10% of patients, “uncom-
mon” side effects occur in .1%–1% of patients, “rare” side
effects occur in .01%–.1% of patients, and “very rare” side
effects occur in <.01% of patients). However, in the United
States, the FDA has not issued specific guidelines for use of
such terms (Aiken 2009; FDA 2009).
Thus, we conducted research to determine whether
there are informal or implicit norms that govern the use of
such “frequency words” in U.S. DTC advertising. First, we
retrieved current DTC print advertisements for 24 prescrip-
tion drugs (including the top 10 brands in 2008 DTC expen-
ditures). Second, we extracted from these advertisements
every side effect description using any variation of the
words “common” or “rare” (e.g., “rare,” “rarely occurring,”
“commonly”). Third, for each side effect, we searched the
product’s “prescribing information” insert for information
on actual incidence rates of that side effect in clinical trials
and postmarketing surveillance. Across all 24 brands’
advertisements, 126 specific side effects were described as
“common,” and 15 specific side effects were described as
“rare.” For 120 of the 126 “common” side effects, we were
able to find the numerical incidence of that side effect in
clinical trials among patients in both the drug treatment and
the placebo conditions. For example, the consumer adver-
tisement for Viagra states that “common side effects for
Viagra include ... facial flushing,” while the package insert
reveals that “flushing” occurs in 10% of clinical trial
patients taking Viagra and 1% of patients given a placebo.
Overall, the 120 side effects described as “common” in
DTC advertising had a median incidence rate of 7.25%
among patients taking the drug (M = 9.51%, SD = 7.98),
which is roughly 4.0% greater than the 3.3% median inci-
dence rate in the placebo group (M = 4.38%, SD = 4.67%).
Both the 7.25% “raw” incidence rate and the 4.0% “incre-
mental” rate are within the 1%–10% range dictated for
“common” side effects in the EU.
Incidence data on side effects described as “rare” were
more elusive, in part because “rare” side effects often do not
emerge in clinical trials (which involve a few thousand
patients) but instead emerge during “postmarketing surveil-
lance” of adverse events. Such data are often difficult to
obtain and interpret (e.g., because of underreporting).
Nonetheless, we were able to glean some norms in drug
companies’ use of the word “rare.” First, drug company
regulatory compliance personnel told us that, in general,
they feel comfortable describing a side effect as “rare” in an
advertisement as long as it is described as “rare” in product
labeling (because the FDA has already approved the label-
ing). Second, we found that many package inserts contain
the following statement: “Rare events are those occurring in
less than 1/1000 patients” (i.e., <.1%, much like the EU
guidelines for “rare” and “very rare”). Finally, the “rare”
side effects on which we could find data typically had inci-
dence rates much lower than .1%. For example, advertise-
ments for Cialis describe “sudden hearing loss” as a “rare”
side effect. This warning is based (Falco 2007) on the FDA
having received 29 reports of sudden hearing loss among
users of all erectile dysfunction brands between 1996 and
2006, a period during which 40 million erectile dysfunction
prescriptions were written. Even if we assume that these 29
reports represent only 5% of all hearing-loss cases among
brand users, the incidence rate would translate into
.00145%, or 1 of every 69,000 prescriptions.
In summary, the FDA has no official guidelines for the
use of words such as “rare” and “common,” but the use of
these terms in U.S. DTC advertising appears to adhere to
norms that are similar to those prescribed in the EU. How-
ever, although words such as “rare” and “common” have
fairly consistent numerical meanings to drug marketers, it
does not necessarily follow that consumers interpret them in
this way (Berry et al. 2003). Research suggests that though
such terms are familiar to most consumers, their numerical
interpretation varies widely from consumer to consumer
(Dhami and Wallsten 2005). Furthermore, research in
Europe suggests that the mean (or median) percentages that
consumers associate with such terms often depart signifi-
cantly from what they are intended to convey. For example,
although British consumers differentiate between frequency
words used in package inserts, they tend to overestimate the
likelihood of adverse events described with these words
(Berry et al. 2003). In particular, British consumers tend to
greatly overestimate the likelihood of adverse events
described as “rare” or “very rare.”
If similar overestimation is shown to occur among U.S.
consumers evaluating DTC messages, this could be a prob-
lem because it might cause consumers to unnecessarily
forgo potentially beneficial medical products and perhaps
expose themselves to even greater risks of product nonuse.
Wosinska (2005) uses an econometric analysis of consumer
sales data to investigate compliance after exposure to DTC
advertisements listing the risks of the cholesterol-reducing
drug Lipitor and finds reduced drug compliance among the
brand’s existing users after the execution of the DTC cam-
paign—an effect the author speculates (but does not test) is
caused by these consumers’ elevated concern about a “rare
but serious side effect” (liver damage) described in the DTC
advertisements. The question for U.S. drug marketers is,
Will similar frequency misperceptions occur when U.S.
consumers evaluate product risk information? Thus, the first
hypothesis is as follows:
H1: When consumers evaluate information on a potentially
risky new product, (a) they tend to overestimate the likeli-
hood of adverse events described as either “very com-
mon” or “very rare” (compared with the actual probabili-
ties these terms are typically used to convey in DTC
advertising), and (b) their overestimation of the likelihood
of an adverse event is most pronounced for events
described as “very rare.”
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Weighing the Severity and Likelihood of Adverse
Product Events
Any risk associated with product use has two important
dimensions: the severity of the potential adverse event and
its likelihood of occurrence. Several accepted models of
how health-related information is processed assume that
consumers make health care decisions based on a rational
evaluation of both frequency and severity. Typically, con-
sumers are assumed to combine severity and frequency in a
multiplicative way, forming global evaluations by weight-
ing the severity (or disutility) of potential outcomes by their
subjective probabilities. This “rational” view of risky deci-
sion making has been formalized with models that predict
independent variables’ (e.g., attitudes, susceptibility, sever-
ity) influence on behavioral intentions in the health belief
model (Berry 2004; Rosenstock 1974), the theory of rea-
soned action (Fishbein and Ajzen 1975), and the heath
action process approach (Schwarzer 2001), among others.
These models have been used because they are predictive in
survey-based correlational studies that evaluate breast self-
examination (Moore, Barling, and Hood 1998) and inten-
tion to have a Pap smear (Barling and Moore 1996), among
other behaviors. These studies imply that consumers can
adequately understand and process the presented risk, bene-
fits, and expected outcomes and thus behave rationally in
their health care decisions.
However, we believe that under certain circumstances,
consumers’ actual weighting of severity and likelihood
information will deviate markedly from these expected util-
ity models—the perception of risk may be dependent on
other elements of the situation. Risk may be evaluated rela-
tive to the perceived benefit (Alhakami and Slovic 1994;
Finucane et al. 2000) or influenced by the frame in which
the message is presented (Cox, Cox, and Zimet 2006).
Weinstein (2000, p. 65) notes that “it is surprising that
empirical studies of health-protective behavior provide little
support for a perceived probability by perceived severity
interaction.” It may be that both frequency and severity
affect the decision process, but it is not a multiplicative rela-
tionship, or it may be that there are situational differences
that determine the relative impact of frequency and severity.
Furthermore, we expect severity to be a stronger force
because research shows that consumers often have a diffi-
cult time differentiating levels of probability but can effec-
tively differentiate levels of payoff (Loewenstein et al.
2001). This research suggests that risk severity information
has a greater influence on consumers’ product use inten-
tions than risk frequency information. However, consumers’
evaluations of risk severity and frequency information may
vary depending on their prior affective state. We discuss this
phenomenon in the next section.
Media Context, Mood, and Product Risk
Media context is an important but understudied aspect of
advertising research (Pelsmacker, Geuens, and Anckaert
2002). Although “real-world” ad exposure almost always
occurs within a specific media context (i.e., advertisements
are embedded in magazines, television programs, and so
forth), most audience testing presents advertisements in a
“media vacuum,” without surrounding program or editorial
material. However, evidence indicates that media context
can affect audience moods and that media-induced moods
can affect how consumers process advertising (e.g.,
Shapiro, MacInnis, and Park 2002).
Yet the effects of media-induced mood on consumers’
responses to product risk information are not obvious.
Three competing streams of research posit different pro-
cesses by which mood influences message evaluation. First,
the “mood-as-information” model suggests that consumers
use mood as a cue to guide information processing and that
positive mood reduces detailed processing (see Schwarz
2001). Second, the “risk-as-feelings” model suggests that
risk elicits feelings that determine the active mood state and
that these risk-induced feelings influence the decision
process (see Slovic et al. 2005). The third stream of
research posits that a positive mood actually increases con-
sumers’ ability to process, use, and extrapolate from infor-
mation in making decisions (Isen 2000). In this section, we
discuss the competing theories’ predictions regarding con-
sumer processing of product risk information.
The mood-as-information model posits that positive-
affect consumers interpret their mood to mean that “all is
well” and then base stimulus judgments on internal,
schema-based knowledge (“top-down” processing) rather
than detailed external information. Those in neutral or nega-
tive moods interpret their mood to mean that “all is not
well” and then tend to process detailed information in the
environment through “bottom-up” processing (Bless et al.
1996; Schwarz 2001; Schwarz and Clore 1983). However,
the findings in this area have been mixed. While some stud-
ies find that positive mood induces reliance on global
evaluations rather than detailed data analysis (Bless,
Mackie, and Schwarz 1992), other research suggests that
positive mood does not decrease processing capacity or
motivation (Bless et al. 1996). Indeed, happy people have
been shown to engage in detail-oriented, effortful process-
ing in some tasks (Bless et al. 1990; Bless et al. 1996).
Fedorikhin and Cole (2004) extend this stream by examin-
ing perceived social risk and suggest that positive mood can
act as a “prime,” activating similarly valenced assessments
of risk. In general, both the mood-as-information and the
affect-priming models suggest a main effect of mood, in
which positive-mood people tend to generate more positive
evaluations than neutral-mood people. In addition, the risk-
as-information model would predict an interaction, in which
the judgments of neutral-mood people (compared with
positive-mood people) are more strongly influenced by both
severity and frequency information because neutral-mood
people are more attuned to the details of the environment.
The risk-as-feelings model suggests that the mood gen-
erated by the evaluated risk would supersede any preexist-
ing mood state (Alhakami and Slovic 1994; Lowenstein et
al. 2001; Slovic et al. 2005). That is, a risky stimulus is
“tagged” with some level of affect that is stored in memory.
Then, “[affect] may serve as a cue for many important judg-
ments (including probability judgments)” (Slovic et al.
2005, p. S36) through a mental shortcut called the “affect
heuristic” (Finucane et al. 2000). Therefore, regardless of
media-induced mood or stated frequency of that side effect,
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participants would reject a product described as having
severe side effects (because it generates negative feelings)
and accept a product described as having mild side effects
(because it generates more positive feelings). Much of the
empirical support for the risk-as-feelings hypothesis relies
on either correlational studies or mood manipulations that
are contained within the same message that presents the
risks and benefits of the underlying activity. Thus, in this
research stream, it is difficult to separate the influence of
mood from the manipulation of risk.
A third stream of research makes different predictions
regarding how mood influences risk processing. This
research stream posits that positive moods (compared with
neutral moods) increase consumers’ ability to discriminate
between important, high-stakes risks and more minor, low-
stakes risks (Isen and Geva 1987). Therefore, although con-
sumers in positive moods may be more likely to disregard
relatively trivial risks than consumers in neutral moods,
they may be reluctant to take large, unjustified risks involv-
ing “meaningful potential losses” (Nygren, Isen, and Taylor
1996, p. 70). In a sense, consumers in good moods should
extrapolate risks to their likely outcomes and evaluate risks
in proportion to their relative importance. This theory helps
explain these and other findings that are difficult to account
for with the mood-as-information, affect-priming, or risk-
as-feelings hypotheses.
Isen (2000) posits that this phenomenon may be part of
a broader pattern, in which people in positive moods are
simply better decision makers (i.e., better able to rationally
weigh and integrate information, as well as interpret the
logical extensions of that information). Research suggests
that positive mood facilitates cognitive flexibility, openness
to new information, and the ability to perceive connections
among potentially related concepts (e.g., Erez and Isen
2002; Isen and Daubman 1984; Murray et al. 1990; for a
review, see Isen 2001). Therefore, this stream of research
would predict that people in a positive mood (compared
with those in a neutral mood) are more likely to use and
interpret all the information in a situation and extend that
information to a likely outcome to make a decision.
We designed the current study to test the conflicting
predictions of the three streams of mood research by inde-
pendently manipulating audience mood and risk presenta-
tion (i.e., frequency and severity). In this way, we set the
opposing hypotheses against one another and expect to find
support for the third stream of research. Therefore, we pro-
pose hypotheses suggested by this third stream of mood
research:
H2: Consumers’ behavioral intentions are influenced by a
three-way interaction among media-induced mood, side
effect severity information, and side effect frequency
information.
a. Among neutral-mood people, behavioral intentions are
influenced by a main effect of severity. Specifically,
neutral-mood people will report significantly lower inten-
tion to use a product with potential side effects that are
severe, regardless of the stated frequency of these side
effects.
b. Among positive-mood people, behavioral intentions are
influenced by an interaction between frequency and sever-
ity. Specifically, positive-mood people will give relatively
little evaluative weight to the severity of side effects
described as “very rare” but substantial weight to the
severity of side effects described as “very common.”
c. Among positive-mood people, the impact of risk frequency
and severity information is mediated by inferences about
other product attributes (e.g., perceived product efficacy).
Method
Overview
To test these hypotheses, we conducted a randomized,
between-subjects experiment, in which a national sample of
young adults was exposed to a brief magazine story
(intended to manipulate mood), followed by a message for a
prescription drug for the early detection of skin cancer. The
experiment varied the frequency and severity of the side
effects described in the product message and independently
varied the mood evoked by the news story. We discuss the
development and pretesting of the experimental stimuli and
then describe the main experiment. Note that by using a
controlled experiment in which mood and risk are indepen-
dently manipulated, we can separate the influence of mood
from the influence of the two manipulated elements of risk
to understand how each affects decision making.
Risk Message Stimuli, Pretests, and Interpretation
of Risk Probability Words
Risk messages. Five versions of a message were devel-
oped for a prescription lotion to detect skin cancer. Each
message version had the same picture (a stylized picture of
the sun) and headline (“Important News for Young Adults
About Skin Cancer”). The body of each message contained
basic information about skin cancer (drawn from the Ameri-
can Cancer Society Web site), which was identical for all
experimental and control groups. The experimental mes-
sages also contained a statement about a potential side
effect, which varied in stated frequency (either “very com-
mon” or “very rare”) and severity (either “a mild headache
that lasts for about an hour” or “an extremely severe
headache that lasts for several weeks and may require medi-
cal treatment to avoid permanent nerve damage”). The con-
trol (no side effect) message stated that “there are no side
effects to this lotion.” (For full wording of the messages, see
the Appendix.)
Risk pretest. To assess participant response to the fre-
quency and severity manipulations, we conducted a pretest
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using a 2 (frequency of side effect: common versus rare) × 2
(severity of side effect: mild versus severe) factorial
between-subjects design, with a control (no side effect). We
summarize the results of this pretest in Table 1. Pretest par-
ticipants were recruited from an introductory business class
at a large midwestern university. A total of 114 volunteers
participated in the pretest and received extra course credit
for their participation. Data were collected using paper-and-
pencil measures. Each participant was assigned randomly to
one of the five target messages and then completed mea-
surement scales to evaluate his or her perceptions of the fre-
quency and severity of the product’s side effects. Partici-
pants assessed perceived side effect likelihood using three
five-point (1 = “strongly disagree,” and 5 = “strongly
agree”) Likert-type scales (i.e., “It is likely that I will
experience some side effects of this lotion”; “If I use this
lotion, I will probably experience some side effects”; “Most
people who use this lotion will experience side effects”).
We measured perceived side effect severity with three state-
ments using the same five-point Likert scale (i.e., “The
potential side effects of this lotion are very serious,” “This
lotion has the potential for very severe side effects,” and
“Using this lotion could lead to very negative conse-
quences”). These scales for perceived likelihood and sever-
ity proved to be reliable (α = .93, and α = .95, respectively).
To test the impact of the manipulations on perceived
side effect severity and likelihood, we ran two two-way
analyses of variance (ANOVAs). The severity manipulation
check showed that perceived severity was influenced solely
by a main effect of stated severity (F(1, 109) = 170.6, p <
.001, η2 = .61) and no other main or interactive effects.
Thus, the severity manipulation appears to be successful
and unconfounded. Furthermore, the reported means show
that perceived severity is in the expected direction (Msevere =
4.2, Mmild = 1.7, Mcontrol = 2.1), and a Bonferroni post hoc
analysis indicated that the severe condition is significantly
higher than either the mild or the control at p < .001, and
the control and mild cell are not statistically different from
each other.
The frequency manipulation check showed that per-
ceived side effect likelihood was influenced by a main
effect of stated frequency (F(1, 109) = 43.2, p < .001, η2 =
.284) in the expected direction (Mcontrol = 2.2, Mrare = 2.7,
Mcommon = 4.0; all ps < .05 in Bonferroni pairwise compari-
sons). Stated severity had no significant main effect on per-
ceived side effect likelihood. However, there was a signifi-
cant frequency × severity interaction on perceived likelihood
(F(1, 109) = 10.5, p = .002, η2 = .088). Frequency descriptors
TABLE 1
Risk Pretest Means (and Standard Deviations)
Mild Side Effect Severe Side Effect No Side Effect
“Rare” “Common” “Rare” “Common” Control Group
n = 22 n = 25 n = 23 n = 22 n = 22
Perceived side effect severity 1.77 1.72 4.28 4.18 2.10
(.86) (.56) (.79) (1.16) (1.10)
Perceived side effect likelihood 2.85 3.49 2.52 4.42 2.20
(1.0) (.75) (1.07) (.71) (1.05)
(common versus rare) had a stronger effect on perceived like-
lihood when describing severe side effects than when describ-
ing mild side effects. Specifically, perceived side effect likeli-
hood was greater among participants in the common/severe
condition (M = 4.42) than among those in the common/mild
condition (M = 3.49; t = 4.3, p < .001, η2 = .295). Although
this effect could be viewed as a potential confound, note
that pretest participants perceived “very common” side
effects as more likely than “very rare” side effects, regard-
less of whether these side effects were mild (Mcommon/mild =
3.49, Mrare/mild = 2.85; t = 2.51, p = .016) or severe (Mcommon/
severe = 4.42, Mrare/severe = 2.52; t = 6.97, p < .001). Nonethe-
less, the main study includes analysis to ensure that these
effects do not provide an alternative explanation of the
results.
Mood Induction Stimuli and Manipulation Checks
To manipulate media-induced mood independently, we
selected several “human interest” news stories from the
national press and made subtle modifications to each of
these stories to elicit either a positive or a neutral mood.
The four stories selected reported on (1) a boy who was res-
cued after being trapped in a “crane” vending machine, (2)
the Soap Box Derby national championship races, (3) the
“Click It or Ticket” seat belt campaign, and (4) a teenager’s
attempt to play on the Ladies Professional Golf Association
tour. Two versions of each story were constructed to repre-
sent positive and neutral versions by changing a few aspects
of each story. For example, the two versions of the golf
story described the teenager either winning the tournament
(positive mood) or merely participating in the tournament
(neutral mood). Eight stories (positive and neutral versions
of the four original stories) were developed.
Affect Pretest 1. Fifty-six respondents were recruited
from an undergraduate business class at a large midwestern
university. Respondents were told that they would be evalu-
ating a short news article and would be asked to report their
feelings about the article. Data were collected through aWeb
survey, in which each participant was randomly assigned to
one of the experimental conditions. After participants read
their assigned article, they were asked the following:
Now, we would like for you to answer some questions
about your feelings while reading this article. Please think
back to the article you just read and think about the feel-
ings and emotions that you experienced during this read-
ing. Please indicate the extent to which you felt each of
these feelings.
Then, they evaluated the article on two of Izard’s (1977)
emotion subscales: happy (“joyful,” “happy,” “delightful”;
α = .94) and sad (“sad,” “down”; α = .88).1 From this initial
pretest, we identified the two stories (golf and seat belt) that
exhibited the largest differences between the positive and
the neutral versions of each of the two articles. We then sub-
jected these four stories (positive and neutral versions of the
golf and seat belt stories) to a second pretest.
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Affect Pretest 2. We conducted the second pretest with
148 students (75 females, 73 males) recruited from intro-
ductory business classes.2 Through the Web survey, each
participant was randomly assigned to one of the four final
article versions. After exposure to the article, participants
responded to Izard’s (1977) emotion scale; we used
summed measures of the happy (α = .95) and sad (α = .89)
subscales to evaluate the mood induced by each article. We
conducted a multivariate analysis of variance (MANOVA)
with mood manipulation (positive versus neutral) and news
article type (golf versus seat belt) as the independent
variables and Izard’s happy and sad subscales as the depen-
dent measures. As we expected, there was no main or inter-
active effect of story type (F(1, 144) < 1.0, not significant
[n.s.]) on either the happy or the sad subscales, suggesting
that both of the story topics could be combined in the analy-
sis. In addition, there was no significant effect on the sad
subscale for any of the main or interactive comparisons
(F(1, 144) < 1.7, n.s.). However, there was a significant main
effect of the happy subscale for the positive versus neutral
conditions (Mpositive = 3.35, Mneutral = 2.89; F(1, 144) = 5.74,
p = .018). Thus, we deemed the selected news articles to be
effective manipulations of media-induced mood.
Method: Main Experiment
To test the hypotheses, we employed a 2 × 2 × 2 between-
subjects full factorial experimental design, with a control
cell representing no side effects. The factors were media-
induced mood (positive versus neutral), product side effect
severity (mild versus severe), and product side effect fre-
quency (very rare versus very common). The manipulations
of mood, side effect severity, and side effect frequency were
identical to those in the pretests.
Participants. Four hundred thirty-four respondents were
recruited from a nationwide sample of Internet users (repre-
senting 49 different states).3 The final sample included 93
participants who were in the control cell (i.e., no side
effects) and 341 participants who viewed a message that
manipulated frequency and severity. The sample was evenly
divided by gender (217 females, 216 males). Thirty-eight
percent of the respondents were ages 18–28, 23% were ages
29–33, 33.1% were ages 34–38, and 6.5% were age 39 or
older. Thus, the majority of participants (more than 94%)
fell in the 18–38 age range, which represents “young
adults” (i.e., the target audience for the messages). More
than 84% had some college or more, 97% had never been
2All the student samples were collected from different classes,
so no student repeated the same study.
3The Internet survey sampling company randomly selected the
Caucasian American respondents from a panel of nearly 9 million
household members, representing more than 3.7 million unique
e-mail addresses worldwide. The panel pool is recruited and
enrolled using banner advertisements and online recruitment
methods, exclusively with permission-based techniques. The sam-
ple participants agree to belong only to this online survey pool and
no other. The pool is used exclusively for research (not sales) pur-
poses and is monitored to ensure that participants complete no
more than four surveys per year. Although the panelists have an
intrinsic motivation to be involved in survey research, they are
offered small rewards with each survey invitation.
1Participants evaluate each mood descriptor word on a five-
point scale, where 1 is “not at all” and 5 is “very much so.”
diagnosed with skin cancer, and more than 80% did not
have an immediate family member who had been diag-
nosed. Random assignment to cells should have distributed
these variables equally across the manipulated cells. To be
sure, we ran a chi-square test on each distribution. For all
three variables, the values are relatively evenly dispersed
across the manipulated cells (i.e., self skin cancer diagnosis,
all cells have two or fewer reported cases; family skin can-
cer diagnosis, χ2 < 1.64, n.s.; and gender, χ2 < .66, n.s.).
Therefore, the sample is considered nonbiased by gender or
history of skin cancer.
Procedure. For each person who responded to the sur-
vey invitation, the first screen on the Web survey presented
an introduction to the study. Participants were thanked for
their participation and were told the following:
In a moment, you will be asked to view a short newspaper
article and an advertisement for a proposed new product.
Please view these as you would normally view articles
and advertisements in a newspaper.... After you have read
the article and the advertisement, please ... begin the ques-
tionnaire. You will be asked to answer some questions
about what you have read and your feelings about the
product.
After respondents read the introduction and agreed to par-
ticipate, they were randomly assigned to one of four ver-
sions of a human interest story (2 story type × 2 mood
level), followed by one of five versions of the target product
message (which varied in the frequency and severity of
stated side effects [plus control] as developed in the
pretests).
Because the experiment included a manipulation of
mood in the form of a human interest story, we wanted to
ensure that the respondents did not guess the purpose of the
study and respond to demand effects. Thus, as a check for
potential demand effects, we conducted a postexperimental
inquiry with a sample of 51 adult respondents ages 20–39
(recruited from the survey sampling online panel) who did
not participate in the main experiment. Each of these
respondents completed the entire experimental procedure
and then was asked two additional questions: “What do you
think is the purpose of this study?” and “What do you think
the researchers expect to find from this study?” None of the
respondents guessed any of the study’s hypotheses. The
majority of respondents stated that the researchers were
interested in measuring and/or increasing young people’s
knowledge about skin cancer risk and skin cancer preven-
tion and detection products. Not a single respondent men-
tioned the role of mood or emotion or made any reference
to the mood induction stimulus (i.e., the news article that
preceded the product message).
Pooling and Manipulation Checks
Because we used two versions of the “news article,” we
conducted a pooling test by running a MANOVA with a
“story version code” as an independent variable along with
the manipulated variables mood, frequency, and severity.
We evaluated the results to determine whether they differed
by story version (i.e., golf story versus seat belt story).
Pooling test results showed no significant results involving
Consumer Response to Drug Risk Information / 37
story version in the overall MANOVA or on any of the indi-
vidual dependent variables evaluated in the study. There-
fore, we conducted all subsequent analyses with the data
pooled across versions.
Perdue and Summers (1986) suggest that manipulation
checks are best conducted in a separate pretest rather than
being included in the main experiment that examines the
dependent variables (e.g., brand attitudes, intentions). They
note (p. 319) that “including these checks in the main
experiment can present problems independent of whether
they come before or after the dependent variable measures.”
Manipulation checks placed before the dependent measures
may bias the latter (e.g., by creating demand effects), while
checks placed after the dependent measures may fail to
detect stimulus effects that are inherently transient, such as
mood inductions (see Vastfjall 2002). Therefore, we relied
on the separate pretest studies to test the effects of the mood
and risk manipulations.
Measures
We assessed “behavioral intention” (BI) by averaging par-
ticipants’ evaluations on two statements (“How likely
would you be to ask your doctor about this product?” and
“How likely would you be to purchase this lotion if it were
available?”) on a seven-point intention scale ranging from
“very unlikely” (1) to “very likely” (7). The resulting scale
was reliable (α = .92).
We assessed “attitude toward product usage” (Attusage)
by measuring participants’ agreement with four statements
adapted from Cox, Cox, and Zimet (2006) (“Overall, I think
this lotion is a very good product,” “Using this product
would be important to me,” “People who use this product
are safer than those who do not,” and “I would rather use
this lotion than any currently available alternative”) on a
five-point scale ranging from “strongly disagree” (1) to
“strongly agree” (5). A factor analysis of these four items
yielded a single factor, on which each item had a loading
greater than .88, which explained 80% of the variance.
Thus, we combined the scores on these four items to form a
mean measure with coefficient alpha of .92.
We assessed “perceived overall product risk” (Overall
Product Risk) by having participants report their agreement
(on a five-point Likert scale) with the statement “Overall,
this lotion is risky.”
We assessed “fear about using the product” (Fear) by
having participants report their agreement (on five-point
Likert scales) with the statements “Using this lotion would
make me worry” and “I would be afraid to use this lotion.”
The coefficient alpha for this mean scale was .90.
We assessed “belief about product efficacy” (Efficacy)
by having respondents report their agreement with the three
statements “This lotion is effective in detecting skin can-
cer,” “This lotion works in detecting skin cancer,” and
“People who use this lotion are less likely to die of skin
cancer” (measured on a five-point Likert-type scale). A fac-
tor analysis of these three items yielded a single factor, on
which each item had a loading greater than .71, which
explained 76% of the variance. Thus, we combined partici-
pants’ scores on these three items to form an averaged mea-
sure with a coefficient alpha of .83.
We assessed “perceived vulnerability to skin cancer”
(Vulnerability) using the two statements “I worry about get-
ting skin cancer” and “I am fearful that I will get skin can-
cer at some time in my life.” Participants evaluated these on
the same five-point “disagree/agree scale” (α = .94).
We assessed “perceived barriers to product use” (Barri-
ers) by having participants report their agreement (same
“disagree/agree scale”) with the four statements “Using this
lotion would be inconvenient,” “Using this lotion would be
embarrassing,” “Using this lotion would be too expensive,”
and “Using this lotion would take too much effort.” A factor
analysis of these four items yielded a single factor, on
which each item had a loading greater than .66, which
explained 67% of the variance. Thus, we combined partici-
pants’ scores on these four items to form an averaged mea-
sure with a coefficient alpha of .84.
In addition, we assessed perceived percentage likeli-
hood by asking a single question: “If you, personally, used
the lotion, what is the percentage chance that you would
experience some side effects? (Please write in the number)
____ %.”
Results
Interpretation of Risk Probability Words
We examined consumers’ numerical interpretation of the
risk language typically used to describe side effects in DTC
prescription drug advertisements. In this analysis, we also
entered respondents’ age category as a factor to determine
whether their estimations of a drug’s side effect frequency
might vary with their overall level of life experience. As we
hypothesized, the data replicate previous findings from
Europe (e.g., Berry et al. 2003) regarding consumers’ inter-
pretation of probability words, such as “rare” or “common.”
That is, although a side effect described as “very common”
is typically used to imply an incidence of approximately
10%, study participants reported their perceived likelihood
of “very common” side effects to be 37.9%. Similarly,
although “very rare” is typically used to convey an actual
side effect incidence of less than .01%, participants esti-
mated their own likelihood of experiencing such side effects
to be much higher (M = 29.03%). Thus, while the estimated
likelihood of side effects differs significantly between the
“very rare” and the “very common” conditions (F = 4.50,
p < .035), participants tend to greatly overestimate the inci-
dence of side effects associated with these verbal descrip-
tors (particularly “very rare”) compared with the actual
probabilities these terms are typically used to convey. The
analysis also indicated that this tendency did not vary sig-
nificant across respondent age groups. Age did not have a
main effect on consumers’ estimated probability of experi-
encing side effects, nor did it moderate the impact of risk
descriptors (“very common” versus “very rare”) on those
perceptions.
Weighing the Severity and Likelihood of Product
Risks
As we noted previously, the economic models of risky deci-
sion making assume that consumers will (or should) give
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decision weight to both the frequency and the severity of
potential product risks, weighting the severity of potential
effects by their respective likelihoods. However, we pre-
dicted that consumers’ evaluations of overall product risk
information in DTC advertisements would deviate
markedly from the predictions of such models. To examine
these effects, we conducted a MANOVA with frequency
and severity as the independent variables and behavioral
intention (BI), attitude toward product use (Attusage), fear of
using the product (Fear), and perceived overall product risk
(Overall Product Risk) as dependent variables. First, the
overall model shows a significant main effect of severity
(F(4, 337) = 22.1, p < .001). Severity had a significant main
effect on all the dependent variables in the expected direc-
tion: BI (Mmild = 4.3 versus Msevere = 3.0; F(1, 337) = 42.2, p <
.001), Attusage (Mmild = 3.5 versus Msevere = 2.9; F(1, 337) =
41.0, p < .001), Fear (Mmild = 2.5 versus Msevere = 3.3;
F(1, 337) = 63.4, p <.001), and Overall Product Risk (Mmild =
2.5 versus Msevere = 3.3; F(1, 337) = 68.3, p < .001). Second,
there was no significant main effect of side effect frequency
in either the overall MANOVA (F(4, 334) = 1.0, p = .41) or
the ANOVAs of the individual outcome variables (η2
ranged from .000 to .004). Third, there is no evidence of
any frequency × severity interaction either in the overall
MANOVA (multivariate F(4, 334) = .81, p = .52) or on any of
the four dependent variables (η2 ranged from .000 to .004).
Thus, in the sample as a whole, the stated severity of a
product side effect has a strong influence on consumers’
product evaluations and perceived risk, while the stated fre-
quency had no effect (main or interactive) on consumers’
product evaluations and intentions. However, as we hypoth-
esized, media-induced mood moderated participants’
responses to product risk frequency and severity informa-
tion. We discuss these effects next.
Consumer Mood and Product Risk Response
In the next analyses, we examine how media-induced mood
influences consumers’ response to product side effect sever-
ity and frequency. We summarize the results of this analysis
in Table 2. As H2 predicted, and contrary to the prediction
of the mood-as-information and risk-as-feelings literature,
there was no main effect of mood on behavioral intention.
However, there was a significant interaction of mood ×
severity × frequency (F(1, 333) = 5.34, p = .021, η2 = .016).
Among neutral-mood participants, behavioral intention
was influenced solely by stated side effect severity (F(1, 171) =
17.1, p < .001, η2 = .09), while stated side effect frequency
had neither main (F = .01, p = .92, η2 = .000) nor interactive
(F = .61, p = .44, η2 = .004) effects on intentions. Thus, as
Figure 1 shows, neutral-mood participants gave essentially
the same evaluative weight to the side effect severity
regardless of whether the side effect was described as “very
rare” or “very common.” This finding is consistent with H2a
but is contrary to most normative models of risky decision
making, suggesting that the utility/disutility of a potential
outcome should be weighted by its likelihood of occurrence.
However, among positive-mood participants, there was
not only a main effect of stated side effect severity on inten-
tion (F(1, 162) = 26.5, p < .001, η2 = .14) but also a significant
frequency × severity interaction (F(1, 162) = 5.93, p = .016,
η2 = .04). As Figure 2 shows, positive-mood participants
give relatively little weight to the severity of a potential side
effect described as “very rare” (Mrare/severe = 3.3, Mrare/mild =
4.1; F(1, 81) = 3.4, p = .07, η2 = .04), but they give substan-
tial weight to the severity of a side effect described as “very
common” (Mcommon/severe = 2.9, Mcommon/mild = 5.2; F(1, 81) =
31.3, p < .001, η2 = .28). This is consistent both with H2b
and with normative models of risky decision making, in
which high-probability events are given greater evaluative
weight than low-probability events. Figure 2 also reveals
that when the product’s potential side effects are mild,
positive-mood participants actually seem to prefer a product
whose mild side effects are described as “very common”
(Mcommon/mild = 5.2) to one whose side effects are “very
rare” (Mrare/mild = 4.1; F(1, 78) = 6.22, p = .015, η2 = .074).
Thus, H2b is supported, but the exact pattern of effects is
particularly noteworthy.
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To better understand this pattern of results, we focused
on the third stream of mood research discussed previously
in this article. This stream predicts that positive-mood
people are more open to unique information and are better
able to detect connections among potentially related con-
cepts (Isen 2001). Thus, it seems reasonable that a person in
a positive mood may use product risk information to make
inferences about other product attributes (see Stewart,
Folkes, and Martin 2001, pp. 351–52), especially product
efficacy or effectiveness (see Ursic 1984). That is, we posit
that positive-mood consumers may make the inference that
if a product has common (albeit mild) side effects, it must
be effective—or what might be called “the Listerine heuris-
tic” (i.e., “if it tastes bad, it must be killing germs”). In this
case, “if they put it on the market with common (albeit
mild) side effects, it must be effective.”
To assess this interpretation, we first examined whether
positive-mood participants’ judgments of a product’s effi-
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TABLE 2
Main Experiment: Cell Means (and Standard Deviations)
Positive Mood Neutral Mood
Mild Side Effect Severe Side Effect Mild Side Effect Severe Side Effect
“Rare” “Common” “Rare” “Common” “Rare” “Common” “Rare” “Common”
(n = 41) (n = 39) (n = 42) (n = 44) (n = 39) (n = 44) (n = 49) (n = 43)
Behavioral intent 4.1 (2.1) 5.2 (1.7) 3.3 (1.9) 2.9 (1.9) 4.2 (1.9) 4.0 (2.1) 2.8 (1.6) 3.0 (1.8)
Attitude toward product
usage 3.5 (1.0) 3.8 (.7) 2.8 (.9) 2.8 (.9) 3.4 (.8) 3.3 (1.0) 2.9 (.8) 3.0 (1.0)
Perceived overall
product risk 2.5 (1.0) 2.6 (1.0) 3.5 (1.0) 3.5 (1.2) 2.4 (.9) 2.4 (.9) 3.2 (1.0) 3.3 (1.0)
Fear about using
product 2.5 (.8) 2.7 (1.0) 3.4 (1.0) 3.5 (1.2) 2.3 (.9) 2.5 (1.0) 3.2 (1.1) 3.3 (1.0)
Perceived product
efficacy 3.4 (.8) 3.8 (.8) 3.2 (.7) 3.4 (.8) 3.3 (.8) 3.3 (.9) 3.2 (.6) 3.3 (.8)
Perceived barriers to
product use 2.6 (.9) 2.4 (.9) 2.6 (.6) 2.6 (.7) 2.3 (.7) 2.5 (.8) 2.7 (.6) 2.8 (.9)
Perceived % likelihood
of side effects 21.1 (30.2) 33.8 (33.3) 38.5 (35.0) 43.3 (33.3) 27.7 (35.6) 33.5 (32.2) 33.8 (32.2) 34.7 (36.5)
Perceived vulnerability
to skin cancer 3.3 (1.1) 3.5 (1.2) 3.1 (1.1) 2.8 (1.2) 3.2 (1.2) 3.1 (1.1) 3.2 (1.0) 3.5 (.9)
cacy are influenced by its side effect frequency. As we pre-
dicted, positive-mood participants perceive a product with
“very common” side effects as having greater efficacy (M =
3.59) than a product with “very mild” side effects (M =
3.27; F(1, 162) = 6.98, p < .01). Among neutral-mood partici-
pants, stated side effect frequency has no impact on per-
ceived efficacy (F(1, 171) = .15, p = .70).
Next, we conducted mediation analysis, examining
whether positive-mood participants’ preference for a prod-
uct whose mild side effects are “very common” (versus
“very rare”) is mediated by perceived product efficacy. We
employed Baron and Kenny’s (1986) mediation test
method, estimating a series of regression models and testing
the significance of the (unstandardized) regression coeffi-
cients. First, a bivariate regression model confirmed that
among positive-mood participants, side effect frequency
(common/mild versus rare/mild) had a significant effect on
behavioral intention (B = 1.08; t = 2.49, p = .015). Second,
a bivariate regression model confirmed that side effect fre-
quency had a significant impact on perceived product effi-
cacy (B = 1.18; t = 2.12, p = .037); that is, positive-mood
participants perceived a product with common/mild side
effects as more effective than one with rare/mild side
effects. Third, we regressed behavioral intention simultane-
ously on both stated side effect frequency and perceived
efficacy. In this model, the proposed mediator (perceived
efficacy) has a significant influence on behavioral intention
(B = .51; t = 7.77, p < .001), while the effect of the inde-
pendent variable (side effect frequency) becomes nonsignif-
icant (B = .47; t = 1.41, p = .164). Thus, the regression
results satisfy all four of Baron and Kenny’s criteria for
establishing mediation. As an additional step, we followed
Baron and Kenny’s further recommendation and tested the
statistical significance of the indirect effect of frequency on
intention, mediated by perceived efficacy (frequency →
perceived efficacy → intention), using the conservative
Sobel (1982) test. This test confirmed the significance of
the proposed mediated path (z = 2.04, p < .05).4
Thus, higher side effect frequency appears to signal
higher product efficacy, and as long as potential side effects
are mild, this makes the product more attractive to positive-
mood participants. However, when potential side effects are
severe, positive-mood participants do not prefer the product
with more frequent side effects. Why is this so? Analysis
indicates that when side effects are mild, perceived product
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risk has little influence on behavioral intentions (rBI,risk =
–.15, p = .18). Instead, positive-mood participants’ intentions
to use a product with mild side effects are driven largely by
their beliefs regarding its efficacy (rBI,efficacy = .68, p <
.001). However, when side effects are severe, positive-mood
participants’ behavioral intentions are more strongly influ-
enced by perceived product risk (rBI,risk = –.46, p < .03), and
efficacy is much less important (rBI,efficacy = .21, p = .054).
Fisher’s z-tests (Cohen and Cohen 1983) confirm that the
intention/risk correlation is significantly higher when side
effects are severe (rBI,risk = –.46) than when they are mild
(rBI,risk = –.15; z = 2.2, p = .028), while the intention/
efficacy correlation is significantly higher when side effects
are mild (rBI,efficacy = .68) than when they are severe
(rBI,efficacy = .21; z = 3.95, p < .001).
Thus, positive-mood participants perceive higher side
effect frequency as signaling higher product efficacy, and as
long as potential side effects are mild, this greater effective-
ness makes the product more attractive. However, if the
product’s potential side effects are severe (i.e., it can lead to
permanent nerve damage), positive-mood participants do
not really care how effective it is.
The results suggest that positive-mood participants not
only use both frequency and severity information in evaluat-
ing the product but also use this information to make infer-
ences about other product attributes (i.e., efficacy), and they
employ these inferences in forming their behavioral inten-
tions. Next, we discuss the implications of these findings.
Discussion
Risk disclosure requirements for DTC advertising are predi-
cated on the assumption that consumers appropriately inter-
pret and weigh this risk information to make informed health
care choices (Calfee 2002; FDA 2004). However, the ques-
tion remains as to how and when consumers use the differ-
ent types of risk information contained in such messages.
This study examines how consumers respond to infor-
mation about the frequency and severity of product risks
and how such responses are moderated by media-induced
affect. We find that consumers tend to greatly overestimate
the actual likelihood of adverse events described with words
such as “common” or “rare” (compared with the probabili-
ties such terms are typically intended to convey) and tend to
give little weight to such probability language when form-
ing product use intentions. However, consumers in positive
media-induced moods seem to engage in more nuanced
evaluation of product risk information, weighing both fre-
quency and severity information and using such information
to make inferences about other product attributes (e.g.,
product efficacy). In the following paragraphs, we explore
these findings in greater depth, discussing their possible
implications for marketers and public policy makers. We
also note some study limitations and suggest directions for
further research.
As we noted previously, most models of risky decision
making assume that consumers will (or should) give
roughly equal weight to hazard severity and frequency.
Many such models posit that these two risk dimensions
have an interactive effect on consumer product evaluations,
4As an alternative explanation of these results, we examined
whether the simple effect of stated side effect frequency (rare ver-
sus common) on behavioral intention (BI) was mediated by par-
ticipants’ perceived percentage likelihood of experiencing side
effects. However, the data do not support this alternative mediation
process. When BI is regressed simultaneously on both stated fre-
quency and perceived side effect likelihood, the proposed mediator
(perceived likelihood) has no significant influence on BI (B = .01;
t = 1.4, p = .165), while the effect of the independent variable
(stated frequency) on BI remains significant (B = .96; t = 2.18, p <
.05). Furthermore, a Sobel test reveals that this alternative mediated
path (frequency→ perceived likelihood→ BI) does not approach
statistical significance (z = .13, p = .897). Similar analyses
revealed that none of the hypothesized effects of the independent
variables on BI were mediated by perceived side effect likelihood.
such that the severity of a potential product hazard is
weighted by its perceived probability. However, we find no
significant main effect of frequency and no frequency ×
severity interaction among neutral-mood participants.
Instead, these consumers’ behavioral intentions were
strongly influenced by a main effect of product side effect
severity. Neutral-mood consumers reported much lower
intentions to use a product with the potential for a severe
side effect, regardless of whether this side effect was
described as “very rare” or “very common.”
Although consumers’ reluctance to use a product that
has any potential to cause severe harm is understandable,
the finding that consumers (or at least neutral-mood con-
sumers) give so little weight to information on the likeli-
hood of such harm should be a matter of some concern. It is
possible for advertisements for medical products to under-
state product risks; however, it is also possible for them to
overstate them. Because medical products often have
important health benefits, such overestimation of risk can
endanger consumers’ health by deterring use of potentially
beneficial products (Stewart, Folkes, and Martin 2001, p.
258). As we noted previously, Wosinska (2005) presents
evidence that the risk warnings in Lipitor advertisements
caused some heart patients to stop taking the medication,
even though the described risk was quite rare. Similarly,
some research suggests that FDA “black box” warnings
about suicidal thoughts associated with antidepressant use
could have actually increased teen suicides by decreasing
antidepressant use among depressed adolescents who really
needed to be taking the medications (Gibbons et al. 2007).
Thus, although there is an understandable push toward more
prominent presentation of product risk information in DTC
advertisements (FDA 2009), there may be a point beyond
which this trend is counterproductive, particularly if con-
sumers disregard information on the (often small) likeli-
hood of the potential adverse event.
However, this study suggests that consumers’ process-
ing of product risk information is influenced by media-
induced mood. Media-induced mood moderated the effects
of product side effect severity and frequency on consumers’
behavioral intent. Specifically, consumers in the positive-
mood condition were influenced by both frequency and
severity information in forming behavioral intent, while
those in the neutral-mood condition were influenced only
by severity information.
Furthermore, the data suggest that positive-mood con-
sumers’ evaluations are driven, at least in part, by infer-
ences about the efficacy of the product. Among positive-
mood participants, higher side effect frequency increases
perceived product efficacy, and if potential side effects are
mild, this makes the product more attractive. However,
when potential side effects are severe, positive-mood par-
ticipants do not prefer the product with more frequent side
effects. Further analysis revealed that when side effects are
mild, positive-mood participants’ product use intentions are
driven largely by beliefs regarding product efficacy. How-
ever, when side effects are severe, positive-mood partici-
pants’ behavioral intentions are more strongly influenced
by perceived product risk, while efficacy becomes much
less important. Thus, positive-mood participants perceive
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higher side effect frequency as signaling higher product
efficacy, and as long as potential side effects are mild, this
greater perceived effectiveness increases their intentions to
use the product. However, if the product’s side effects are
severe, positive-mood participants do not really care how
effective it is. (By analogy, if a consumer discovers that a
Ford Pinto can explode on rear impact, he or she may not
really care whether the gas-tank placement increases gas
mileage.) In summary, the findings suggest that positive-
mood participants not only use both frequency and severity
information but also use this information to make inferences
about other product attributes (i.e., efficacy) and employ
these inferences in forming their behavioral intentions.
These data are consistent with H2 and are inconsistent
with the mood-as-information and risk-as-feelings theories
of how mood influences decision making. The mood-
as-information theory (see Bless et al. 1996) predicts that
positive-mood participants would base their product judg-
ments on their general schema or “activated stereotype” for
the broad product category, thus giving little weight to the
“specifics of the situation” (i.e., to detailed product attribute
information presented in the message). However, we find
that positive-mood participants are more sensitive to detailed
product information presented in the message, weighing
information on both side effect frequency and severity and
elaborating on this detailed information to make inferences
about other product attributes (i.e., efficacy).
Alternatively, the risk-as-feelings literature predicts that
the feelings generated by product risk information would
overshadow participants’ prior mood states, and there would
be no significant influence of media-induced mood on the
dependent variables. However, the data show an interaction
of mood and risk (mood × frequency × severity) with
behavioral intent. Thus, the data are most consistent with
the predictions of the third stream of mood research we
described previously; that is, consumers who are in a
media-induced positive mood state (compared with neutral-
mood consumers) are more willing to take small risks (mild
side effects), particularly when greater efficacy is inferred
from the frequency descriptors.
This finding suggests that the positive-mood consumer
is more willing to take the presented information and
extrapolate it into efficacy implications, while the neutral-
mood consumer is focused only on the most salient piece of
information presented (i.e., severity) and translates this
information into an overall assessment of risk. This result is
consistent with the third stream of mood literature we dis-
cussed previously, which suggests that consumers in a posi-
tive mood are more likely to generate more unusual and
diverse first associates (Isen et al. 1985) and to understand
metaphors (Roehm and Sternthal 2001).
Implications for Managers and Regulators
The results of this study have several potential implications
for both marketers and regulators of risky products, espe-
cially products intended to prevent or treat disease. Impor-
tantly, this study suggests that consumers make fuller use of
product risk information when they are in a positive affec-
tive state. Although it is difficult for marketers or policy
makers to control the particular mood of a consumer when
he or she is evaluating product risk information, it may be
possible to influence his or her mood state when processing
such information. For example, advertisers might present
positive mood induction stimuli (e.g., pleasant images)
within the advertisement itself (though such stimuli should
be presented before presentation of risk information, not
concurrently, to avoid interference with consumer reception
of risk information). Alternatively, positive mood induction
might be achieved through media placement—that is, by
inserting product risk messages within media environments
(e.g., specific magazines) that are likely to create a mood
conducive to risk-message processing. Some critics of DTC
advertising may be alarmed by such recommendations, con-
cluding that such positive mood inductions are designed to
make consumers blithely ignore product risk information.
However, that is not what we found—again, positive-mood
consumers appear to be more attuned to the nuances of prod-
uct risk information than neutral-mood consumers. Indeed,
it might be fruitful for further research to explore whether
positive affect enhances the processing of risk information
in other, nonadvertising settings (e.g., whether the presence
of pleasant, low-stress atmospherics in a clinical setting
enhances patients’ ability to weigh potential risks and bene-
fits when considering surgery and other medical treatments).
In addition, the results of this study suggest that mar-
keters and regulators need to find more effective ways of
communicating the frequency (or likelihood) of potential
product risks to consumers. The marketing literature con-
tains excellent research on how the format of product risk
information influences consumer awareness of a potential
product hazard (e.g., Bettman, Payne, and Staelin 1986;
Hoy and Andrews 2004; Stewart, Folks, and Martin 2001).
However, much less attention has been paid to communicat-
ing the actual frequency with which such adverse events
occur. For some products, such frequency communication
may not be important. Some products (e.g., household
cleansers; Bettman, Payne, and Staelin 1986) have hazards
that are avoidable if the product is used as directed, while
other products (e.g., tobacco, illegal drugs) are so harmful
that risk communicators may not care whether consumers
greatly overestimate the risk of adverse events. However,
consumers evaluating medical treatments need to weigh the
risks of product use carefully against the risks of product
nonuse. Without an understanding of relative risk probabili-
ties, consumers may overestimate extremely low-likelihood
risks (e.g., a life-threatening drug reaction) and underesti-
mate higher-likelihood events (e.g., getting the disease the
drug is intended to prevent). Therefore, it is important that
marketers and regulators explore alternative approaches to
communicating risk frequency information to consumers.
Limitations and Further Research
This study has several limitations that should be addressed
in further research. First, although this study found that
positive media-induced affect can alter consumers’
responses to product risk information, further research
should broaden this line of investigation and examine the
potential impact of specific negative media-induced emo-
tions (e.g., anger, fear, sadness) on consumer interpretation
of product risk information.
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Second, the participants in this study were relatively
young adults (a national sample of adults approximately
18–40 years of age, with a median age of about 30). This
was an appropriate audience for the messages (young adults
are a prime target audience for skin cancer prevention prod-
ucts), and several DTC campaigns target this age group (e.g.,
the DTC campaign for the human papillomavirus vaccine
Gardasil is targeted toward young women and girls). How-
ever, it should be noted that many DTC advertisements tar-
get older adults suffering from chronic ailments. There may
be differences in how older adults process risk information
in such messages, both because of age-related information-
processing differences and because of older adults’ greater
direct experience with the risks associated with both dis-
eases and treatments. Therefore, we urge researchers to
examine the phenomena studied herein with older adults.
More broadly, it would be fruitful for researchers to exam-
ine how individual differences other than age (e.g., health
literacy, overall risk aversion) may moderate consumer pro-
cessing of risk frequency and severity information.
Third, as is the case with many marketing communica-
tion experiments, this study presented consumers with mes-
APPENDIX
Risk Message Stimuli
Important News for Young Adults about Skin
Cancer
Skin cancer is the most common form of cancer
among people in their twenties. Every 53 minutes,
someone dies of skin cancer. Skin cancer can be
hard to see with the naked eye, or may look like a
normal mole or freckle.
Fortunately, there is now a medicated lotion which
can detect skin cancer. This product is not a sun
block or sun screen. It is applied by a doctor to the
patient’s skin, and creates a gentle reaction which
allows the doctor to easily detect the early develop-
ment of skin cancer. This lotion is highly effective.
[There are no side effects of using this lotion].
A [very common/very rare] side effect of using this
lotion is a [mild headache that lasts for about an
hour/an extremely severe headache that lasts for
several weeks and may require medical treatment
to avoid permanent nerve damage].
For more information, call 1-800-4CANCER,
or talk to your doctor.
sages for a new, unfamiliar product so that they would have
no prior information about the product and its risks. Pre-
senting participants with information about existing brands
creates some additional complications because the effects
of presented information must be untangled from prior
brand beliefs and attitudes. However, despite these method-
ological challenges, researchers could extend this line of
research to the study of familiar brands. In particular, it
would be useful to examine how the presentation of risk
information affects the decision of existing product users to
continue (or discontinue) use of the product.
Finally, further research should examine a broad range of
approaches for communicating risk frequency information
to consumers, including verbal, numerical, and graphical
approaches. As we show in this study, verbal communica-
tion of risk (using adjectives such as “rare” or “common”)
is widely used by marketers, but it is problematic. Such
words are inherently ambiguous, and lay interpretations of
risk terms often deviate dramatically from the intent of risk
communicators. Numerical presentations of likelihoods
(e.g., odds, percentages, probabilities) have the advantage
of greater precision but also present communication prob-
lems. Research suggests that many people find percentages
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and probabilities to be confusing (Berry 2004; Tversky and
Kahneman 1981) and uninvolving (Cox and Cox 2001).
However, some research suggests that presenting con-
sumers with “natural frequencies” (e.g., “Of every 10,000
people who take this medicine, approximately 30 people
will have a seizure”) may be clearer than percentages or
probabilities (e.g., Slovic, Monohan, and MacGregor 2000).
In addition, Schwartz, Woloshin, and Welch (2009) recently
showed that placing numerical drug- and placebo-outcome
information in a “drug facts box” in DTC advertisements
(similar to nutritional labeling on food packaging) can
improve consumer understanding of the drug’s benefits and
risks. Finally, a promising method of overcoming some of
these problems may be the graphical presentation of risk
likelihoods. Some research suggests that graphical risk pre-
sentations can be processed more rapidly (Paivio 1971) and
can increase both risk comprehension and intention to adopt
risk-reduction behaviors (e.g., Cox et al. 2010). Therefore,
further research should examine whether graphical methods
improve consumers’ ability to assess product risk and effi-
cacy information in DTC advertisements of prescription
drugs and other risky products.
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